Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 8—August 2025
Research Letter
Seroprevalence of Rift Valley and Crimean-Congo Hemorrhagic Fever Viruses, Benin, 2022–2023
Figure 2

Figure 2. ELISA reactivity showing seroprevalence of Rift Valley and Crimean-Congo hemorrhagic fever viruses, Benin, 2022–2023. IgG ELISA (ID.Vet, https://bioadvance.life/en/id-vet-2) for RVFV with a sample/negative percentage <40.0 is considered positive. IgG ELISAs (Euroimmun, https://www.euroimmun.com; Panadea Diagnostics, https://www.panadea-diagnostics.com) for CCHFV with a ratio >1.1 are considered positive according to the manufacturer. A) RVFV competitive ELISA (ID.Vet) using nucleoprotein as antigen. Positive samples, n = 10/650. B) CCHFV indirect ELISA (Euroimmun) using nucleoprotein as antigen. Positive samples, n = 40/650. C) CCHFV immune complex capture ELISA (Panadea) using nucleoprotein as antigen. Positive samples, n = 5/92). D) Reduced indirect IgG ELISA reactivity of CCHFV (Euroimmun) with poly-L-histidine concentrations of 0.01, 0.05, 0.10, 0.50, 1.00, and 2.00 mg/mL. Box plots shown sample distribution, displaying medians (thick lines within boxes) and interquartile ranges (box top and bottom edges); whiskers indicate 1.5× interquartile range. Red lines show cutoff levels for ELISAs; gray shading shows the area for borderline results; black triangles show samples positive by RVFV immunofluorescence assay; blue triangles show samples positive by CCHFV immunofluorescence assay. The Spearman correlation was performed in R, and boxplots for RVFV and CCHFV were plotted using the ggplot2 package in R (https://www.r-project.org). Because of the low detection rates of RVFV-specific and CCHFV-specific IgG, negative reverse transcription PCR results, and low serum volumes, we did not perform IgM analyses. CCHFV, Crimean-Congo hemorrhagic fever virus; RVFV, Rift Valley fever virus.